EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neurocognitive test performance following cancer among middle‐aged and older adults in the Hispanic Community Health Study/Study of Latinos ( HCHS / SOL ) and the SOL‐Investigation of Neurocognitive Aging Ancillary Study

Humberto Parada iD, Margaret S Pichardo iD, Linda C Gallo iD, Gregory A Talavera iD, Corinne McDaniels-Davidson iD, Frank J Penedo iD, David J Lee, Wassim Tarraf, Tayna P Garcia, Martha L Daviglus, Hector M González iD

Cancer Medicine · 2023

DOI: 10.1002/cam4.5863 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Humberto Parada und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Epidemiology and Biostatistics, School of Public Health, San Diego State University, San Diego, California, USA. Hauptthemen laut MEDLINE: Neoplasms, Cognition Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NCI NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer patients and survivors often experience acute cognitive impairments; however, the long‐term cognitive impact remains unclear particularly among Hispanics/Latinos. We examined the association between cancer history and neurocognitive test performance among middle‐aged and older Hispanic/Latinos.

Methods

Participants included 9639 Hispanic/Latino adults from the community‐based and prospective Hispanic Community Health Study/Study of Latinos. At baseline (2008–2011; V1), participants self‐reported their cancer history. At V1 and again at a 7‐year follow‐up (2015–2018; V2), trained technicians administered neurocognitive tests including the Brief‐Spanish English Verbal Learning Test (B‐SEVLT), Word Fluency Test (WF), and Digit Symbol Substitution Test (DSS). We used survey linear regression to estimate the overall, sex‐specific, and cancer site‐specific [i.e., cervix, breast, uterus, and prostate] adjusted associations between cancer history and neurocognitive test performance at V1 and changes from V1 to V2.

Results

At V1, a history of cancer (6.4%) versus no history of cancer (93.6%) was associated with higher WF scores (β = 0.14, SE = 0.06; p = 0.03) and global cognition (β = 0.09, SE = 0.04; p = 0.04). Among women, a history of cervical cancer predicted decreases in SEVLT‐Recall scores (β = −0.31, SE = 0.13; p = 0.02) from V1 to V2, and among men, a history of prostate cancer was associated with higher V1 WF scores (β = 0.29, SE = 0.12; p = 0.02) and predicted increases in SEVLT‐Sum (β = 0.46, SE = 0.22; p = 0.04) from V1 to V2.

Conclusion

Among women, a history of cervical cancer was associated with 7‐year memory decline, which may reflect the impacts of systemic cancer therapies. Among men, however, a history of prostate cancer was associated with improvements in cognitive performance, perhaps due in part to engaging in health promoting behaviors following cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsCognition DisordersAgedFemaleHumansMaleMiddle AgedAgingHispanic or LatinoMental Status and Dementia TestsNeuropsychological TestsProspective StudiesProstatic NeoplasmsSelf ReportUterine Cervical Neoplasms

Stichwörter der Autor:innen

cancercancer survivorscognitive declinecognitive functionneurocognitive testing

Autor:innen und Institutionen

  • Division of Epidemiology and Biostatistics, School of Public Health, San Diego State University, San Diego, California, USA.
  • UC San Diego Health Moores Cancer Center, La Jolla, California, USA.
  • Department of Surgery, Hospitals of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Psychology, San Diego State University, San Diego, California, USA.
  • Division of Health Promotion and Behavioral Science, School of Public Health, San Diego State University, San Diego, California, USA.
  • Departments of Psychology and Medicine, University of Miami College of Arts and Sciences and Miller School of Medicine, Miami, Florida, USA.

ORCID-Profile: Humberto Parada, Margaret S Pichardo, Linda C Gallo, Gregory A Talavera, Corinne McDaniels-Davidson, Frank J Penedo, Hector M González

Förderung

  • NIA NIH HHS
  • NCI NIH HHS
  • NHLBI NIH HHS
  • Division of Cancer Prevention, National Cancer Institute
  • National Heart, Lung, and Blood Institute
  • National Institute on Aging

Zitieren

APA

Parada, H., Pichardo, M. S., Gallo, L. C., Talavera, G. A., McDaniels-Davidson, C., Penedo, F. J., Lee, D. J., Tarraf, W., Garcia, T. P., Daviglus, M. L., & González, H. M. (2023). Neurocognitive test performance following cancer among middle‐aged and older adults in the Hispanic Community Health Study/Study of Latinos ( HCHS / SOL ) and the SOL‐Investigation of Neurocognitive Aging Ancillary Study. Cancer Medicine. https://doi.org/10.1002/cam4.5863

Vancouver

Parada H, Pichardo MS, Gallo LC, Talavera GA, McDaniels-Davidson C, Penedo FJ, et al. Neurocognitive test performance following cancer among middle‐aged and older adults in the Hispanic Community Health Study/Study of Latinos ( HCHS / SOL ) and the SOL‐Investigation of Neurocognitive Aging Ancillary Study. Cancer Medicine. 2023. doi:10.1002/cam4.5863

BibTeX
@article{Parada2023,
  author = {Parada, Humberto and Pichardo, Margaret S and Gallo, Linda C and Talavera, Gregory A and McDaniels-Davidson, Corinne and Penedo, Frank J and Lee, David J and Tarraf, Wassim and Garcia, Tayna P and Daviglus, Martha L and González, Hector M},
  title = {Neurocognitive test performance following cancer among middle‐aged and older adults in the Hispanic Community Health Study/Study of Latinos ( HCHS / SOL ) and the SOL‐Investigation of Neurocognitive Aging Ancillary Study},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.5863}
}
Kostenlos starten →